AbCellera Biologics, Inc. is a Canadian Pharmaceuticals company with a Risk Rating Score of 28.7, indicating a Medium Risk assessment. The company utilizes its ESG platform to accelerate antibody discovery and development, providing precise clinical candidates in a timely manner. AbCellera Biologics has a proven track record of successful partnerships with emerging biotechs and pharmaceutical companies, leveraging proprietary tools and data science for optimized solutions.